Data from: Bristol stool scale: Patient versus expert score data
Data files
Jun 28, 2024 version files 69.56 KB
-
BSS_data_deidentified.xlsx
68.74 KB
-
README.md
814 B
Jun 28, 2024 version files 69.71 KB
-
BSS_data_deidentified.xlsx
68.74 KB
-
README.md
972 B
Abstract
The Bristol Stool Scale (BSS) is one of the most commonly used tools for evaluation of stool consistency. BSS ranges from 1-7 and each score is assigned to a given consistency of the feces. Self-reported characterizations can differ from an expert evaluation, and the reliability of BSS is unclear. The dataset consists of BSS scores by patients with inflammatory bowel disease collected throughout a 3-year follow-up, matched with scores assessed by experienced bioengineers (experts). The purpose of the study where data was collected was to compare patient scores to expert scores and hence determine the reliability of the BSS.
https://doi.org/10.5061/dryad.djh9w0w7r
The dataset consists of Bristol Stool Scale (BSS) scores as assessed by patients and by experienced bioengineers (experts).
NOTICE: The original files published on June 14, 2024, have been removed due to non-compliance with Dryad guidelines for publishing human subjects data.
Description of the data and file structure
Column 1 lists individual patient numbers. Each patient has scored 1-4 fecal (timepoints 0, 3 months, 6 months and 3 years; there may be missing values that are left out) samples by using the BSS. The patient scores are listed in column 2. Each sample has also been scored by an expert, and these values are listed in column 3. BSS is a 7-point ranking system, where types 1-2 and 6-7 correspond to abnormal defecation with constipation and diarrhea, respectively. Empty cells represent missing data.
The data set consists of Bristol Stool Scale (BSS) scores as assessed by patients and by experienced bioengineers (experts). The study is a sub-study of IBSEN-III - a population-based observational inception cohort with prospective follow-up (Clinical Trials ID: NCT 02727959). The cohort consist of newly diagnosed IBD patients and symptomatic non-IBD controls living in the South-Eastern Health Region of Norway, included during a 3-year period from 2017 to 2019.